Aslanidis C, Ries S, Fehringer P, Büchler C, Klima H, Schmitz G
Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, 93042, Germany.
Genomics. 1996 Apr 1;33(1):85-93. doi: 10.1006/geno.1996.0162.
Cholesteryl ester storage disease (CESD) and Wolman disease are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (LAL). We provide evidence that the strikingly more severe course of Wolman disease is caused by genetic defects of LAL that leave no residual enzyme activity. In a CESD patient, a G --> A mutation at position -1 of the exon 8 splice donor site results in skipping of exon 8 in 97% of the LAL hnRNA originating from this allele, while 3% are spliced correctly, resulting in full-length LAL enzyme. The mutant LAL mRNA codes for a protein lacking amino acids 254 to 277. On the other allele, a G --> T mutation leads to a premature stop codon at Gly245, resulting in inactive LAL enzyme. In addition, the previously identified Leu179 --> Pro mutation is present on this allele, and the LAL mRNA is rendered unstable by the premature stop codon. Analysis of two children with Wolman disease showed that both were homozygous for a G --> A mutation at position +1 of the same splice donor site as for the CESD patient, leading to skipping of exon 8. In contrast to the CESD patient, no correctly spliced mRNA was detectable. We have also expressed a wildtype LAL cDNA and the mutant LAL cDNA from one Wolman patient in Sf9 and H5 insect cells. We demonstrate that the LAL enzyme generated from the wildtype LAL cDNA was active in homogenates from Sf9 and H5 cells, while the enzyme with the internal deletion of 24 amino acids originating from the LAL cDNA of the Wolman patient was not. The combined data provide evidence that the only functionally relevant genetic difference between the Wolman patients and the CESD patient is that the splice defect in Wolman, which affects one of the invariable nucleotides of the splice consensus sequences (position +1), does not permit any correct splicing, whereas the defect observed in CESD (position -1) allows some correct splicing (3% of total LAL mRNA) and therefore the synthesis of functional enzyme.
胆固醇酯贮积病(CESD)和沃尔曼病均为常染色体隐性疾病,与溶酶体酸性脂肪酶(LAL)活性降低及基因缺陷相关。我们提供的证据表明,沃尔曼病病情明显更严重是由LAL基因缺陷导致无残余酶活性所致。在一名CESD患者中,外显子8剪接供体位点-1处的G→A突变导致源自该等位基因的97%的LAL hnRNA跳过外显子8,而3%剪接正确,产生全长LAL酶。突变型LAL mRNA编码的蛋白质缺少氨基酸254至277。在另一个等位基因上,G→T突变导致在Gly245处出现提前终止密码子,产生无活性的LAL酶。此外,该等位基因上存在先前鉴定出的Leu179→Pro突变,提前终止密码子使LAL mRNA变得不稳定。对两名沃尔曼病患儿的分析表明,两人在与CESD患者相同的剪接供体位点+1处均为G→A突变的纯合子,导致外显子8跳过。与CESD患者不同,未检测到正确剪接的mRNA。我们还在Sf9和H5昆虫细胞中表达了一名沃尔曼病患者的野生型LAL cDNA和突变型LAL cDNA。我们证明,野生型LAL cDNA产生的LAL酶在Sf9和H5细胞的匀浆中具有活性,而源自沃尔曼病患者LAL cDNA的内部缺失24个氨基酸的酶则无活性。综合数据提供的证据表明,沃尔曼病患者与CESD患者之间唯一功能上相关的基因差异在于,沃尔曼病中的剪接缺陷影响剪接共有序列的一个不变核苷酸(位置+1)且不允许任何正确剪接,而CESD中观察到的缺陷(位置-1)允许一些正确剪接(占总LAL mRNA的3%),因此可合成功能性酶。